Skip to main
  1. Stocks
  2. OrthoPediatrics
  3. Forecast
KIDS

OrthoPediatrics (KIDS) Stock Forecast & Price Target

OrthoPediatrics (KIDS) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 13%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

OrthoPediatrics is benefiting from a visible new-product super-cycle, with 3Q26 revenue of $72.7mn rising 18.6% y/y and beating expectations by about 6%, while Trauma & Deformity and Scoliosis both posted strong gains from share takeaways, broader adoption, and new launches. Management’s raised FY26 revenue guide of $270mn-$273mn, alongside reiterated adjusted EBITDA of $25mn and full-year free cash flow breakeven expectations, suggests the company is gaining operating leverage even as near-term EBITDA reflects timing headwinds and investment in growth. Looking ahead, the business appears positioned for durable upside because many launches remain in limited rollout, international growth is still early, and higher-ASP products should improve margins, contracting leverage, and cash generation into 2027 and beyond.

Bears say

OrthoPediatrics is facing a negative fundamental setup because its current and new products may fail to generate sufficient revenue, while share gains and margin expansion could also fall short of expectations. As the company continues to penetrate the pediatric orthopedic TAM, the scope for meaningful growth acceleration appears limited, reducing the odds of a valuation rerating. Competitive pressure from established healthcare firms or smaller differentiated entrants, along with concentration risk, M&A integration risk, and liquidity risk, could further pressure market share, pricing, and quarterly results.

OrthoPediatrics (KIDS) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OrthoPediatrics and is not a guaranteed prediction by Public.com or investment advice.

OrthoPediatrics (KIDS) Analyst Forecast & Price Prediction

Get the latest OrthoPediatrics (KIDS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in OrthoPediatrics (KIDS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OrthoPediatrics (KIDS) Forecast

Analysts have given OrthoPediatrics (KIDS) a Strong Buy based on their latest research and market trends.

According to 8 analysts, OrthoPediatrics (KIDS) has a Strong Buy consensus rating as of Oct 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OrthoPediatrics (KIDS)


OrthoPediatrics (KIDS) Analyst Forecast & Price Prediction

Get the latest OrthoPediatrics (KIDS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in OrthoPediatrics (KIDS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover KIDS stock data and trends